Michael Williams is a Visiting Scientist in the Langer Lab at MIT’s Koch Institute for Integrative Cancer Research and an Adjunct Faculty Member in the School of Science, Technology and Health Sciences at Eastern Oregon University. Previously he served as Chief Technology Officer at SyneCor, LLC where he co- founded multiple companies, Chief Technology Officer at Synergy Life Sciences and Vice President of Science and Technology at Medtronic AVE. Also, while at Medtronic, Williams founded and was the divisional VP and General Manager of the Neurovascular Technologies Division that was responsible for bringing to market the world’s first neurovascular stent and delivery system. He was also responsible for the vascular divisions pre-clinical, biological and materials research. Before joining AVE, Williams held senior management and engineering positions at Microvena Corporation, Guidant’s Advanced Cardiovascular Systems and Baxter Healthcare’s Pharmaseal Division.
In his work Williams has been on the forefront of multiple new technology frontiers including single application multi-dose vaccine delivery systems, therapeutic live cell immuno-isolation, metallic stents, bioresorbable drug delivery stents, minimally invasive surgical systems, neuromodulation for CHF, vascular brachytherapy, controlled release drug delivery, iontophoretic drug delivery, photodynamic therapy, vascular gene therapy and neurovascular interventions.
Educated at California Polytechnic State University, San Luis Obispo Williams holds 64 issued patents, has coauthored a book chapter as well as several technical papers and abstracts and has been an invited speaker at various technical, scientific and clinical conferences.